amylin pharmaceuticals biopharmaceutical founded based san diego california company engaged discovery development commercialization drug candidates treatment diabetes obesity diseases amylin produced three drugs symlin pramlintide acetate byetta exenatide bydureon exenatide extended release amylin pharmaceuticals cofounded howard e greene jr former ceo san diego biotech pioneer hybridtech develop treatment diabetes synthetic analog amylin discovered researchers oxford university earlier greene served ceo amylin completed ipo needed amylin natural form sticky clumping needles forming little rocksclarification needed pancreas create synthetic version reliable easy work researchers amylin pharmaceuticals altered amino acids molecule result new drug named amylin pharmactietucals signed agreement johnson johnsons lifescan division develop phase ii study made public january showed pramlintide safe mix leading shortacting intermediateacting commercial insulin products preliminary results suggesting might improve glycemic initial phase iii trial results released august demonstrated statistically significant results type juvenileonset diabetes helping modestly improve glucose control without increasing risk hypoglycemia low blood sugar also improving weight cholesterol levels patients adultonset type diabetes pramlintide showed significant benefits six months march seven months next trial data due johnson johnson terminated partnership amylincitation needed joseph c cook jr veteran eli lilly co amylin board member since came retirement taking title chief executive officer cook reduced companys workforce percent conserve cash raised capital investors keep symlin moving regulatory october amylin received approvable letter symlin fda requiring additional clinical data addressing concerns severe hypoglycemia type december fda issued second approvable letter requesting clinical data identify patient population method use symlin increased risk significant hypoglycemia added benefit clearly counterbalances potential increases episodes march symlin approved fda use diabetics difficulty maintaining glycemic october dr john eng licensed amylin peptide isolated venom gila similar human gut hormone responsible regulating insulin glucagon unlike human however halflife several hours making much better drug amylin developed exenatide synthetic version eli lilly signed agreement amylin million partner development may byetta commercial name exenatide approved united july bristolmyers squibb announced would acquire amylin pharmaceuticals part acquisition astrazeneca made billion cash payment make amylin wholly owned subsidiary within existing bmsaz joint venture april bristolmyers squibb announced would close amylins san diego operations end merge amylin manufacturing facility west chester ohio fieldbased sales personnel bristolmyers squibb december astrazeneca purchased bristolmyers squibb share diabetes joint venture result became sole owner former amylin products business including manufacturing facility west chester february us fda approved myalept metreleptin analog human replacement therapy treat complications leptin deficiency addition diet patients congenital generalized acquired generalized metraleptin originally developed amylin november aegerion pharmaceuticals made million cash payment astrazeneca acquire commercialize httpsenwikipediaorgwikiamylinpharmaceuticals